VICX Therapeutics

VICX Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer by targeting the VISTA (V-domain Ig suppressor of T cell activation) pathway. Spun out from the MD Anderson Cancer Center, the company leverages the research of founder Dr. Michael Curran to address the immunosuppressive tumor microenvironment that limits the efficacy of current checkpoint inhibitors. Its lead candidate, VICX-001, is a first-in-class monoclonal antibody designed to block VISTA and reprogram myeloid cells to enhance anti-tumor immunity. The company is currently advancing its pipeline through early-stage clinical trials for patients with advanced solid tumors.